Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Indian (NIFTY) Pharma Industry Analysis

UpdatedMay 11, 2026
DataAggregated Company Financials
Companies181
  • 7D4.1%
  • 3M8.7%
  • 1Y12.1%
  • YTDn/a

Over the last 7 days, the Pharma industry has risen 4.1%, driven by gains from Sun Pharmaceutical Industries of 2.2%. This means that the industry has gained 12% over the past year. Looking forward, earnings are forecast to grow by 16% annually.

Industry Valuation and Performance

Has the Indian Pharma Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Mon, 11 May 2026₹21.9t₹4.4t₹630.3b29.3x34.7x5x
Wed, 08 Apr 2026₹19.8t₹4.3t₹621.1b26.3x31.8x4.5x
Fri, 06 Mar 2026₹20.4t₹4.3t₹621.2b26x32.9x4.7x
Sun, 01 Feb 2026₹19.5t₹4.2t₹606.9b28.6x32.2x4.6x
Tue, 30 Dec 2025₹20.3t₹4.2t₹614.5b28.4x33x4.8x
Thu, 27 Nov 2025₹20.5t₹4.2t₹611.5b29.5x33.6x4.9x
Sat, 25 Oct 2025₹20.4t₹4.1t₹592.0b30.2x34.4x5x
Mon, 22 Sep 2025₹20.7t₹4.1t₹587.9b32x35.3x5.1x
Wed, 20 Aug 2025₹20.4t₹4.1t₹589.0b30.8x34.6x5x
Fri, 18 Jul 2025₹21.1t₹4.0t₹594.1b32.7x35.5x5.3x
Sun, 15 Jun 2025₹20.4t₹4.0t₹595.3b33.7x34.3x5.1x
Tue, 13 May 2025₹19.2t₹3.9t₹565.9b29.6x33.9x4.9x
Thu, 10 Apr 2025₹18.3t₹3.9t₹559.2b27.3x32.7x4.7x
Sat, 08 Mar 2025₹18.7t₹3.9t₹559.4b28.4x33.5x4.8x
Mon, 03 Feb 2025₹19.6t₹3.9t₹543.8b30.5x36.1x5.1x
Wed, 01 Jan 2025₹21.4t₹3.8t₹527.0b34.2x40.5x5.6x
Fri, 29 Nov 2024₹20.2t₹3.8t₹526.7b33.1x38.4x5.3x
Sun, 27 Oct 2024₹20.6t₹3.7t₹495.0b37x41.6x5.5x
Tue, 24 Sep 2024₹21.4t₹3.7t₹492.6b41.1x43.4x5.7x
Thu, 22 Aug 2024₹20.7t₹3.7t₹492.6b36.8x41.9x5.6x
Sat, 20 Jul 2024₹18.6t₹3.6t₹449.9b34.5x41.3x5.2x
Mon, 17 Jun 2024₹17.7t₹3.6t₹448.3b32.3x39.4x5x
Wed, 15 May 2024₹16.9t₹3.5t₹428.5b33.5x39.4x4.8x
Fri, 12 Apr 2024₹17.1t₹3.5t₹418.9b33.5x40.9x4.9x
Sun, 10 Mar 2024₹17.1t₹3.5t₹418.7b33.4x40.8x4.9x
Tue, 06 Feb 2024₹16.4t₹3.4t₹411.4b34.2x39.8x4.8x
Thu, 04 Jan 2024₹15.6t₹3.4t₹395.9b34.8x39.3x4.6x
Sat, 02 Dec 2023₹14.3t₹3.4t₹395.1b31.6x36.2x4.2x
Mon, 30 Oct 2023₹12.8t₹3.3t₹375.3b28.8x34.2x3.9x
Wed, 27 Sep 2023₹12.9t₹3.3t₹369.5b29.8x34.9x3.9x
Fri, 25 Aug 2023₹13.0t₹3.3t₹367.0b29.5x35.3x4x
Sun, 23 Jul 2023₹12.2t₹3.2t₹342.7b26.1x35.7x3.9x
Tue, 20 Jun 2023₹11.4t₹3.2t₹342.4b26.4x33.4x3.6x
Thu, 18 May 2023₹10.4t₹3.1t₹309.6b26.6x33.7x3.4x
Price to Earnings Ratio

33.7x


Total Market Cap: ₹10.4tTotal Earnings: ₹309.6bTotal Revenue: ₹3.1tTotal Market Cap vs Earnings and Revenue0%0%0%
Indian Pharma Industry Price to Earnings3Y Average 36.5x202420252026
Current Industry PE
  • Investors are relatively neutral on the Indian Pharmaceuticals industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PE ratio of 36.5x.
  • The industry is trading close to its 3-year average PS ratio of 4.8x.
Past Earnings Growth
  • The earnings for companies in the Pharmaceuticals industry have grown 27% per year over the last three years.
  • Revenues for these companies have grown 12% per year.
  • This means that more sales are being generated by these companies overall, and subsequently their profits are increasing too.

Industry Comparison

How does Indian Pharma compare with similar industries?

IN Market2.14%
Healthcare4.36%
Pharma4.10%
Pharma4.10%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SUNPHARMA Sun Pharmaceutical Industries₹1.87k2.7%
+₹118.0b		11.1%PE41.2x
500420 Torrent Pharmaceuticals₹4.52k6.3%
+₹90.4b		39.6%PE67.3x
MANKIND Mankind Pharma₹2.47k9.3%
+₹87.1b		-1.2%PE57.1x
AUROPHARMA Aurobindo Pharma₹1.49k8.0%
+₹64.2b		23.3%PE24.8x
ZYDUSLIFE Zydus Lifesciences₹956.956.1%
+₹54.9b		8.1%PE19.5x

Latest News

AARTIPHARM
₹742.85
Aarti Pharmalabs
7D
-7.8%
1Y
-7.1%
WOCKPHARMA
₹1,625.60
Wockhardt
7D
14.1%
1Y
28.0%
Analysis Article • 3h

Wockhardt's (NSE:WOCKPHARMA) Strong Earnings Are Of Good Quality

When companies post strong earnings, the stock generally performs well, just like Wockhardt Limited's ( NSE:WOCKPHARMA...
500420
₹4,519.25
Torrent Pharmaceuticals
7D
6.3%
1Y
39.6%
500257
₹2,245.65
Lupin
7D
-4.5%
1Y
10.0%
MANKIND
₹2,468.80
Mankind Pharma
7D
9.3%
1Y
-1.2%
EMCURE
₹1,678.00
Emcure Pharmaceuticals
7D
-6.4%
1Y
61.8%
AUROPHARMA
₹1,486.60
Aurobindo Pharma
7D
8.0%
1Y
23.3%
Narrative Update • May 05

AUROPHARMA: Margin Reliance On US Approvals Will Expose Execution Weakness

Analysts have nudged their price target for Aurobindo Pharma slightly higher to about ₹1,038 from roughly ₹1,034, citing updated assumptions that combine more cautious revenue growth with higher profit margin expectations and a modestly lower future P/E multiple. Analyst Commentary Recent research on Aurobindo Pharma sits in a cautious zone, even with the slightly higher price target.
AETHER
₹1,200.70
Aether Industries
7D
-4.1%
1Y
49.0%
LAURUSLABS
₹1,266.80
Laurus Labs
7D
8.6%
1Y
113.5%
500124
₹1,279.70
Dr. Reddy's Laboratories
7D
-0.6%
1Y
7.1%
Narrative Update • May 03

500124: Future Tax Compliance And Regulatory Setbacks Will Curb Share Price Upside

Analysts have kept their fair value estimate for Dr. Reddy's Laboratories steady at ₹1,024, explaining that small adjustments to revenue growth, profit margin and future P/E assumptions did not materially change their overall price target view. What's in the News Health Canada granted Dr. Reddy's a Notice of Compliance for its generic Semaglutide Injection, allowing commercialization and sale in Canada.
500488
₹27,777.00
Abbott India
7D
9.2%
1Y
-7.5%
CIPLA
₹1,304.90
Cipla
7D
-2.3%
1Y
-13.7%
GLENMARK
₹2,347.30
Glenmark Pharmaceuticals
7D
-1.9%
1Y
69.9%
Narrative Update • Apr 29

GLENMARK: Future US Respiratory Launches Will Still Leave Earnings At Risk

Analysts have fine tuned their outlook on Glenmark Pharmaceuticals, with the updated price target now set around ₹1,532. This reflects adjustments to assumptions on revenue growth, profit margins and forward P/E that they view as better aligned with the current fundamentals.
SUNPHARMA
₹1,872.70
Sun Pharmaceutical Industries
7D
2.7%
1Y
11.1%
ZYDUSLIFE
₹956.95
Zydus Lifesciences
7D
6.1%
1Y
8.1%
Narrative Update • Apr 27

ZYDUSLIFE: Diabetes And Renal Pipeline Expansions Will Shape A Measured Outlook

Analysts have slightly reduced their fair value estimate for Zydus Lifesciences, lowering the price target from about ₹993.73 to ₹985.41, as updated assumptions around revenue growth, profit margin and future P/E are incorporated into their refreshed model. What's in the News Zydus received final USFDA approval for Dapagliflozin tablets, 5 mg and 10 mg, a type 2 diabetes treatment with US annual sales of about US$10.49b, and later became eligible for 180 days of shared generic exclusivity upon full approval, with manufacturing based at its SEZ, Ahmedabad facility (Key Developments).
RUBICON
₹951.45
Rubicon Research
7D
-2.6%
1Y
n/a